Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects

Published:2014-03-26 Issue:9 Volume:54 Page:968-978
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Lowe Stephen L.¹,Wong Conrad J.²,Witcher Jennifer²,Gonzales Celedon R.²,Dickinson Gemma L.²,Bell Robert L.²,Rorick-Kehn Linda²,Weller MaryAnn³,Stoltz Randall R.⁴,Royalty Jane⁴,Tauscher-Wisniewski Sitra²

Affiliation:

1. Lilly-NUS Centre for Clinical Pharmacology; National University of Singapore; Singapore Singapore

2. Eli Lilly and Company; Lilly Corporate Center; Indianapolis IN USA

3. inVentiv Health Clinical; Ann Arbor MI USA

4. Covance Clinical Research Unit, Inc.; Evansville IN USA

Funder

Eli Llly and Company

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcph.286/fullpdf

Reference31 articles.

1. Discovery of aminobenzyloxyarylamides as kappa opioid receptor selective antagonists: application to preclinical development of a kappa opioid receptor antagonist receptor occupancy tracer;Mitch;J Med Chem,2011

2. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders;Rorick-Kehn;Neuropharmacology,2014

3. Trial watch: opioid receptor blocker shows promise in phase II depression trial;Harrison;Nat Rev Drug Discov,2013

4. Buprenorphine treatment of refractory depression;Bodkin;J Clin Psychopharmacol,1995

5. Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked?;Heilig;Addict Biol,2010

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Green Metrics and Sustainability in Photocatalysis;ChemCatChem;2024-01-22

2. Asymmetric Reduction of Cyclic Imines by Imine Reductase Enzymes in Non‐Conventional Solvents;ChemSusChem;2023-11-15

3. Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine;Life Sciences;2023-08

4. Migraine Treatment: Towards New Pharmacological Targets;International Journal of Molecular Sciences;2023-07-31

5. Kappa Opioid Receptor Antagonism Rescues Genetic Perturbation of Dopamine Homeostasis: Molecular, Physiological and Behavioral Consequences;2023-05-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3